Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
被引用次数：4918 相关文章

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - The Lancet …, 2011 - Elsevier
BACKGROUND: Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - The Lancet …, 2011 - infona.pl
Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor
(TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy …

[引用][C] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C ZHOU - Lancet Oncol, 2011 - cir.nii.ac.jp
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802) : a multicentre, open-label …

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The Lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The Lancet …, 2011 - europepmc.org
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[PDF] practiceupdate.net

[PDF][PDF] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFRmutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - Lancet …, 2011 - cloudfront.practiceupdate.net
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The Lancet …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

[引用][C] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - The Lancet …, 2011 - cir.nii.ac.jp
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label …

[引用][C] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …

C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Lancet …, 2011 - Elsevier Limited